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Abstract 
 
Background: The presentation of COVID-19 overlaps with common influenza symptoms. There 
is limited data on whether a specific symptom or collection of symptoms may be useful to 
predict test positivity.   
 
Methods: An anonymous electronic survey was publicized through social media to query 
participants with COVID-19 testing. Respondents were questioned regarding 10 presenting 
symptoms, demographic information, comorbidities and COVID-19 test results. Stepwise logistic 
regression was used to identify predictors for COVID positivity.  Selected classifiers were 
assessed for prediction performance using receiver operating characteristic analysis (ROC).   
 
Results: One-hundred and forty-five participants with positive COVID-19 testing and 157 with 
negative results were included. Participants had a mean age of 39 years, and 214 (72%) were 
female.  Smell or taste change, fever, and body ache were associated with COVID-19 positivity, 
and shortness of breath and sore throat were associated with a negative test result (p<0.05). A 
model using all 5 diagnostic symptoms had the highest accuracy with a predictive ability of 82% 
in discriminating between COVID-19 results. To maximize sensitivity and maintain fair 
diagnostic accuracy, a combination of 2 symptoms, change in sense of smell or taste and fever 
was found to have a sensitivity of 70% and overall discrimination accuracy of 75%.   
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Conclusion: Smell or taste change is a strong predictor for a COVID-19 positive test result.  Using 
the presence of smell or taste change with fever, this parsimonious classifier correctly predicts 
75% of COVID-19 test results. A larger cohort of respondents will be necessary to refine 
classifier performance.  
 
Introduction 
In mid-January 2020, the World Health Organization (WHO) reported 41 cases of a 
novel coronavirus infection that presented with fever, shortness of breath (SOB), and invasive 
pneumonic infiltrates on chest radiography.1 Since that initial report, this novel coronavirus, 
now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread 
globally, with confirmed cases in almost every country.2 
With the swift spread of cases resulting in the virus’ diseased state known as COVID-19, 
development of reliable assessment methodologies to accurately predict and diagnose COVID-
19 infection is paramount to controlling its spread.   Currently, the availability of COVID-19 
testing remains a limited resource. Insufficient access to testing supplies and reagents highlights 
the need to selectively restrict test kit usage to a relatively limited number of individuals. Many 
patients, including healthcare workers, are not tested as they do not meet “testing criteria” due 
to lack of an identifiable positive contact, lack of travel to a highly infected area or lack of the 
common screening symptoms.  
While publicized symptoms for COVID-19 include fever, fatigue, cough and shortness of 
breath,3,4 several studies have also reported chemosensory dysfunction, such as anosmia and 
ageusia as common findings in COVID positive patients.5-7 Although upper respiratory infections 
are known to cause hyposmia in general,8 in COVID-19 patients, these symptoms can present in 
the absence of other nasal symptoms, suggesting that they are related to direct viral damage to 
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the chemosensory system.5,9 Within the United States, a study of COVID-19 tested subjects 
revealed a significant association of smell and taste impairment in COVID-19 positive patients.10 
A survey study of 417 European COVID-19 patients identified cough, myalgia and loss of 
appetite as the most common general presenting symptoms, with a significant percentage 
(86%) of patients noting smell dysfunction.11 Based on these reports, it appears that smell and 
taste changes may be significant findings to consider when screening for COVID-19 infection.12  
Several studies have developed prediction models for COVID-19, most of which have 
focused on prognostic factors for survival.13 A few prediction models for diagnosis have been 
published, but have mostly identified chest computed tomography (CT) and other laboratory 
findings as predictors.14 One COVID-19 diagnostic model identified the following key symptoms: 
fever, fatigue, shortness of breath, headache and sore throat.15 Smell and taste change have not 
been evaluated in any prediction models to date.  We sought to address this information gap and 
included smell and taste change to construct prediction models for COVID-19 positivity.  We 
aimed to identify a parsimonious subset of symptoms that would enable a clinically tractable 
classifier to predict COVID-19 positivity to improve both decision making on test resource 
allocation and evidence-based counseling of concerned patients. 
 
Methods  
The study was reviewed by the University of California, San Francisco (UCSF) 
Institutional Review Board and was given exempt status (IRB# 20-30530).  With the objective of 
obtaining a large number of responses over a short time period during this highly critical time 
of data collection and dissemination, an anonymous survey was publicized through several 
social media outlets.   The public survey link was posted on social media venues including 
Facebook, Twitter, Reddit, and Nextdoor targeting participant volunteers who had been tested 
or quarantined for COVID-19 symptoms.  Anonymous, self-reported responses were collected 
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between March 31, 2020 and April 10, 2020.  Groups of healthcare workers treating COVID-19 
patients were also targeted.  Recruitment included participants who identified as older than 18 
years and had a history of prior COVID-19 testing or history of being quarantined for symptoms 
of COVID-19.  To avoid bias, the survey title, “UCSF COVID-19 Symptom Survey,” and questions, 
focused on broad COVID-19 symptoms and presentation. Respondents reported COVID-19 test 
results, demographic information and COVID-19 related comorbidities.  The survey included 
forced choice, binary (yes/no) questions about the presence of 10 symptoms in the 2 weeks 
leading up to their test or quarantine:  change in smell or taste, fever or chills, unexplained body 
aches, new sore throat, shortness of breath, new headache, new or worsened cough, nasal 
congestion, nausea or diarrhea, and runny nose.  
 
Database Management and Statistical Analysis 
 Data were collected and managed using Research Electronic Data Capture tools hosted 
at UCSF (REDCap Consortium, Vanderbilt University, Nashville, TN), and Microsoft Excel 
(Microsoft Corp, Redmond, WA).   
 Statistical analysis was preformed using Statistical Package for the Social Sciences 
version 26 (SPSS, IBM Corp., Armonk, NY).  Demographic information was reported using 
descriptive statistics and univariate analysis was used to evaluate the incidence of each 
presenting symptom.  Using the self-reported COVID-19 positive result, analysis was performed 
for each individual significant symptom to determine sensitivity = [true positives / (true 
positives + false negatives)] and specificity = [true negatives / (true negatives + false positives)]. 
Stepwise, forward selection, binary logistic regression was performed with COVID-19 test result 
as the dependent variable and presence or absence of each classic COVID-19 symptom, gender, 
number of comorbidities, age and presence of chronic lung disease as independent variables to 
determine significant predictors for COVID-19 positivity.   The stepwise regression included 
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thresholds of p=0.05 for entry and 0.10 for removal with maximum iterations set at 20 and 
classifier cutoff at 0.5. This analysis was used to determine the best predictors for COVID-19 
positive test results. To assess for potential effects of all symptoms and confounders, all 14 
variables were also entered in a full logistic regression model. Fourteen potential predictor 
variables were assessed for our cohort of 145 COVID positive subjects, which met the goal 
events per candidate predictor of 10 (Hosmer and Lemeneshow rule) to avoid model 
overfitting.16  
Internal validation of the predictors identified was performed using a randomly 
generated sample of 75% of the cohort (development set). This cohort was used to create a 
stepwise logistic regression model that was tested on the remaining 25% of the cohort 
(validation set), and classifier performance was examined.  Cases without missing information 
(n=246) were used for internal validation. 
Receiver operating characteristic (ROC) curves were created to assess predictor 
performance after selecting relevant symptom classifiers based on the regression model and 
clinical utility.  Area under the curve (AUC) analysis was performed to assess the ability of 
symptom classifiers to discriminate COVID positive subjects from COVID negative subjects.  
Statistical significance was set at p-value less than 0.05 for all analyses. 
 
Results 
Study Participants 
 Six hundred and twenty participants enrolled in the study between March 31, 2020 and 
April 10, 2020.  Three hundred and thirty-nine participants reported a prior COVID-19 test, 145 
subjects (43%) had a positive test result (COVID+), 157 subjects (46%) reported a negative test 
result (COVID-), and 37 (11%) reported no result or uncertain result.  Participants who 
reported a positive or negative test result (n=302) at the time of the survey were included in 
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this analysis. The cohort was predominantly female with a higher proportion of females in the 
COVID negative group (Table 1).  Eleven (4%) respondents had been hospitalized (8 COVID+ 
and 3 COVID-, p =0.095). There were no differences in age, race or ethnicity between positive 
and negative COVID-19 test groups. A higher percentage of COVID–19 negative patients 
reported chronic lung disease from asthma, COPD, or emphysema as compared to COVID–19 
positive participants (2(1, N = 302) = 5.69, p = 0.017). 
 
Symptom Presentation 
Based on self-reporting of the 2 weeks prior to undergoing COVID-19 testing or 
initiating quarantine for symptoms, the presence of fever, smell or taste change and body aches 
were significantly associated with a positive diagnosis of COVID-19, whereas shortness of 
breath and sore throat were associated with a negative COVID-19 test result (Table 2). 
Incidence, sensitivity and specificity of each symptom queried for COVID-19 test result 
discrimination are shown in Table 2.  Unexplained body aches demonstrated the highest 
sensitivity (80%) in univariate analysis, while change in smell or taste had the highest 
specificity (73%).  Only one participant with a positive COVID test result reported none of the 
10 symptoms. 
 
Determining Predictors of COVID-19 
Stepwise, forward selection, binary logistic regression analysis was performed to 
determine the predictor variables associated with a COVID positive test result.  The five 
classifier variables identified as the best predictors included the presence of smell or taste 
change, unexplained body aches, fever or chills, shortness of breath, and sore throat.  Variables 
that fell out of the stepwise regression model, and were not significant in the analysis, included 
age, gender, history of lung disease, number of comorbidities, and presence of cough, 
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rhinorrhea, nasal congestion, headache, or nausea or diarrhea.  Each step in the model was 
statistically significant (p < 0.005), the final model (step 5) accounted for 44% of the variability 
of the outcome (Nagelkerke R2 = 0.44) and the Hosmer and Lemeshow test demonstrated 
p>0.05 for all model steps denoting good model fit.   Smell or taste change was the strongest 
predictor identified and when used as a sole classifier, accounted for 24% of the variability in 
the COVID positive test outcome (Nagelkerke R2 = 0.24).  Table 3 shows the logistic regression 
coefficient, Wald test, and odds ratio for each of the predictor variables and models.  Fever or 
chills, smell or taste change, and myalgia were positively associated with a COVID positive test.  
Based on the step 5 predictor model created, the odds ratio for smell or taste change shows that 
when holding all other variables constant, an individual who reports smell or taste change is 7.4 
times more likely to have a COVID positive test than one who does not report smell or taste 
change.  Although significant, the effect of fever and myalgia was smaller than the effect from 
smell or taste change.  An individual who reports fever is 2.4 times, and a person with myalgia is 
3.1 times more likely to have a COVID positive test.  Reported shortness of breath and sore 
throat were associated with a COVID negative result.  Inverted odds ratios indicate that the odds 
of COVID negative result were 5 times higher if shortness of breath was reported and 3.3 times 
higher if sore throat was reported (Table 3).  Full binary logistic regression with all 14 variables 
was done to evaluate the effect of all symptoms and potential confounders.  The analysis 
identified the same 5 symptom variables as significant predictors and the other variables were 
not significant.  Smell or taste change was associated with the largest odds ratio for COVID-19 
positivity. Adjusted odds ratios were similar to the final model in the stepwise logistic 
regression (Supplemental table 1).  
 
Classifier Performance and Discrimination 
The selected predictors from the regression model were internally validated by splitting 
the cohort into a random 75% set (n =184) for classifier development and a 25% (n=62) set, 
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which was used for validation.  Stepwise logistic regression performed on the development set 
produced the same 5 predictors as when the analysis was run on the entire cohort.  Table 4 
shows the performance of the predictor model on the development and validation cohorts.  
Accuracy is defined as the sum of true positive and true negative cases relative to the total 
number of cases.  The final predictor model created was able to correctly classify 74% of COVID 
positive test results and 71% of COVID negative results for an overall accuracy of 73% for the 
validation set.   Accuracy of the validation set was within 3.5% of the development set.   
 
Using classifiers identified from the regression model and clinical judgment, we chose to 
evaluate classifier discrimination for smell or taste change alone and with the presence of fever, 
myalgia, fever and myalgia, or absence of sore throat.  To assess the discrimination ability of 
symptom predictor combinations, sensitivity and specificity analysis were performed and ROC 
curves were plotted.  AUC analysis to measure classifier performance using the presence of 
smell or taste change with either fever and/or myalgia showed fair diagnostic accuracy 
(AUC=0.75, Table 5) with 75% correct discrimination of COVID positivity.   Very good classifier 
performance (AUC = 0.82) required the inclusion of all 5 statistically modeled predictors 
(change in smell or taste, fever, myalgia, sore throat and shortness of breath).17 
 
Discussion 
In this study, we aimed to assess the symptoms associated with a COVID-19 positive test 
in an outpatient population of individuals who were suitably healthy to complete the survey. 
While we included smell and taste questions in our survey, we recruited any participant with a 
COVID-19 test result regardless of specific symptoms. The goal of determining symptom-based 
predictors for COVID-19 was to better define those at risk for COVID-19 infection for test 
resource allocation and patient counseling. Through logistic regression, we have identified and 
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assessed the ability of symptom sets to accurately classify subjects as COVID–19 positive. 
Symptoms associated with COVID-19 positivity included the change to smell or taste, presence 
of fever and body aches, and absence of shortness of breath and sore throat. While our findings 
differ from a European study that identified cough and GI symptoms as common in COVID-19,11 
our results are similar to other published work which reported both loss of smell and absence of 
sore throat in COVID-19 positive patients with an adjusted odds ratio of 10.9 for COVID-19 
positivity if anosmia was reported.10 We have similarly identified smell or taste change as the 
symptom with the strongest correlation to a COVID + result, accounting for 24% of the variance 
in COVID test results.  Variation most likely relates to differences in geographic locale and 
sample cohort COVID-19 severity. 
When screening patients for COVID-19 positivity during this pandemic, is it important to 
consider both data driven information and reasoned clinical judgment. The statistical model 
using 5 diagnostic variables showed the highest overall accuracy of 82%, but the sensitivity of 
this model was low at 56%. Given the importance of a screening protocol with high sensitivity 
and exercising clinical judgment responsive to an evolving pandemic, we chose to assess 
performance of classifiers with the following symptoms: 1) presence of smell or taste change 
and fever and 2) presence of smell or taste change and myalgia.  Both prediction models 
performed very well with sensitivities between 69-70%, specificity of 73%, and overall 
discrimination accuracy of 74-75%. The diagnostic accuracy of adding either fever or myalgia to 
smell or taste change was minimal. We believe that either of these models are clinically 
reasonable when considering COVID-19 patients, and both also performed well statistically. 
Based on the favorable general health status of our outpatient study cohort constituted 
by younger adults with relatively few comorbidities and reasoned clinical judgment of symptom 
progression in severe COVID-19 infection, we chose to exclude absence of shortness of breath in 
prediction model performance analysis.  As shortness of breath was found to be negatively 
associated with COVID-19 positivity in the statistical model, we reported the association.  We do 
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not recommend inclusion of shortness of breath as a negative predictor of disease because it is a 
marker of more severe COVID-19 disease that may not have been captured in the surveyed 
cohort. Chronic lung disease was found to be more common in COVID-19 negative participants 
in this analysis and may be related to patients with lung disease seeking testing and medical 
treatment more frequently than their healthy counterparts. Moreover, our data suggest that a 
higher proportion of males were COVID-19 positive, but we cannot exclude selection bias in 
seeking testing or in participating in an online survey.  
Limitations of this study include dependence on retrospective self-reporting with risk of 
recall bias regarding symptoms, possible duplicate entries, and selection bias of respondents to 
an anonymous online survey posted on social media. Due to the anonymous nature of this study 
and wide circulation to participants across the country, respondents were asked to self-report 
their COVID-19 results leading to potential erroneous responses.  Additionally, COVID-19 test 
performance indices are variable across testing locations, and specifics regarding testing 
procedures were not assessed, possibly contributing to variance in prediction model 
performance.  While we are not able to review patient medical records in this study, model 
validation results confirm that drawing from a large and diverse pool of subjects mitigates risk 
of self-report errors from degrading prediction models in a significant manner. Lastly, we 
acknowledge that patient symptoms may change over time during the duration of their illness 
and asymptomatic and atypical presentations of COVID–19 have been reported.18,19 Therefore, 
while our models will be helpful for identification of at-risk patients, it is important to remain 
vigilant for less common presenting symptoms of COVID–19.  
Online tools are under development for individual risk assessment of infection, and data 
to support these risk calculations will be extremely useful. The cohort evaluated in this study 
was relatively healthy, and able to participate in an online study. The survey responses may not 
reflect diverse populations of the United States, as age and race were not significant factors in 
our analysis. While our work is exploratory, it represents one of the first steps to construct 
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accurate predictor models for COVID-19 positivity. Further work should include hospitalized 
patients to develop a more comprehensive prediction model that may be deployed broadly 
across the United States and abroad. More robust methods for prediction model development 
will require larger data sets and cross-validation studies. 
 
Conclusion 
Chemosensory function change is strongly associated with a COVID-19 positive test.   In 
an outpatient population with few comorbidities, combining symptoms of smell or taste change 
with fever and/or myalgia predicts COVID-19 positivity with fair accuracy.  We believe that this 
information is highly valuable at a time in which testing resources remain highly constrained 
and important decisions must be made regarding testing resource allocation. While not a 
surrogate for testing, using predictive symptoms to determine pre-test probability for COVID-19 
positivity can inform next steps in clinical decision-making under uncertain circumstances. 
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Figure Legend 
 
 
Figure 1.  Receiver operating characteristic (ROC) plots for symptom classifier models.  The 
dashed diagonal line shows a non-diagnostic result.  Area under the curve (AUC) for each 
symptom classifier group is displayed in Table 5. 
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TABLE 1.  Demographic Information 
 
COVID + COVID - 
2 
or F 
  p-value 
Total n (%) 145 (48%) 157 (52%)    
 
Age, years mean (SD) 40 (13) 38 (11) 8.32 0.33 
Sex, female n (%) 94 (65%) 120 (78%) 6.37 0.01* 
Number of Comorbidities n (%)   5.05 0.17 
    0 120 (83%) 113 (72%)   
1 20 (14%) 36 (23%)   
    2 4 (3%) 6 (4%)   
   ≥3 1 (0.7%) 2 (1%)   
Presence of chronic lung disease n 
(%) 
13 (9%) 29 (18%) 
5.70 
 
0.02* 
 SD = standard deviation, *p<0.05 denotes significance 
COVID + = COVID-19 positive test; COVID - = COVID-19 negative test 
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TABLE 2.  Symptom Features 
 
 
COVID + COVID- Sensitivity Specificity p-value 
n (%) n (%) [95% CI] [95% CI] 
 
Unexplained body 
aches 
112 (77%) 87 (55%) 
80%  
[72% – 86%] 
44% 
[36% - 52%] 
< 0.001 
Fever or chills 106 (73%) 82 (52%) 
73%  
[65% – 80%] 
47% 
[39% - 56%] 
< 0.001 
Change in smell or 
taste 
95 (66%) 42 (27%) 
70%  
[61% - 77%] 
73% 
[65% - 80%] 
< 0.001 
New sore throat 59 (41%) 107 (68%) 
70% 
[62% - 77%] 
54% 
[44% - 63%] 
< 0.001 
Shortness of breath 50 (34%) 81 (52%) 
53% 
[45% - 61%] 
62% 
[53% - 70%] 
0.009 
New headache 93 (64%) 90 (57%)   0.085 
New or worsened 
cough 
79 (54%) 104 (66%)   0.070 
Nasal congestion 68 (47%) 61 (39%)   0.082 
Nausea or diarrhea 64 (44%) 62 (39%)   0.347 
Rhinorrhea 52 (36%) 54 (34%)   0.652 
CI = Confidence Interval; p<0.05 denotes significance 
COVID + = COVID-19 positive test; COVID - = COVID-19 negative test 
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TABLE 3. Stepwise Logistic Regression, Predictors for COVID Positive Test Result 
  Predictor(s) B Wald p-value Odds Ratio 
          [95% CI] 
Step 1 Smell or taste change 1.92 44.2 <0.001 6.8 [3.9-12.0] 
            
Step 2 Smell or taste change 2.27 47.4 <0.001 9.7 [5.1-18.5] 
 
Shortness of breath -1.30 15.2 <0.001 0.3 [0.1-0.5] 
            
Step 3 Smell or taste change 2.22 43.0 <0.001 9.2 [4.7 - 17.8] 
 
Shortness of breath -1.69 21.4 <0.001 0.2 [0.1-0.4] 
 
Fever or chills 1.20 12.8 <0.001 3.3 [1.7-6.4] 
       
Step 4 Smell or taste change 2.17 39.4 <0.001 8.7 [4.4-17.2] 
 
Shortness of breath -1.58 18.0 <0.001 0.2 [0.1-0.4] 
 
Fever or chills 1.29 12.8 <0.001 3.6 [1.8-7.1] 
 
New sore throat -0.97 9.1 0.003 0.4 [0.2-0.7] 
       
Step 5 Smell or taste change 2.01 32.6 <0.001 7.4 [3.7-14.8] 
 
Shortness of breath -1.74 20.2 <0.001 0.2 [0.1-0.4] 
 
Fever or chills 0.87 5.3 0.021 2.4 [1.1-5.0] 
 
New sore throat -1.16 11.6 0.001 0.3 [0.2-0.6] 
  Body aches 1.14 7.9 0.005 3.1 [1.4-7.0] 
Variable(s) entered on: 
Step 1: Smell or taste change 
Step 2: Shortness of breath 
Step 3: Fever or chills 
Step 4: New sore throat 
Step 5: Body aches 
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TABLE 4.  Classifier Validation 
        
    
 
Development Set (n=184) 
 
Validation Set (n=62) 
  Predictors 
Sensitivi
ty 
Specifici
ty 
Accura
cy 
Sensitivi
ty 
Specifici
ty 
Accura
cy 
    
  
   Step 
5 
Smell or taste 
change 77.9 74.5 76.1 74.1 71.4 72.6 
 
Shortness of 
breath 
  
  
   
 
Fever or chills 
  
  
   
 
New sore throat 
  
  
    Body aches        
Accuracy = (True positive cases + True negative cases)/Total number of cases 
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TABLE 5.  Classifier Performance 
  
Predictor Set AUC Sensitivity Specificity 
Odds Ratio 
[95% CI] 
p-value 
      
Smell or taste change 0.71 70 73 
6.18 
[3.71-10.29] 
<0.001 
      
Smell or taste change 
Myalgia 
0.74 69 73 
6.20 
[3.71-10.33] 
<0.001 
     
      
Smell or taste change 
Fever  
0.75 70 73 
6.33 
[3.79-10.56] 
<0.001 
     
      
Smell or taste change 
Myalgia 
Fever  
0.75 69 74 
6.35 
[3.79-10.63] 
<0.001 
     
     
      
Smell or taste change 
Sore throat 
0.75 67 74 
5.74 
[3.41-9.69] 
<0.001 
     
      
Smell or taste change 
Myalgia 
Fever  
Sore throat 
Shortness of breath 
0.82 56 89 
8.93 
[5.59-19.76] 
<0.001 
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AUC = Area under the curve, CI = Confidence Interval, p-value<0.05 denotes significance 
                
 
 
 
